+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Ramucirumab"

From
Lung Cancer Drugs Market Report 2025 - Product Thumbnail Image

Lung Cancer Drugs Market Report 2025

  • Report
  • April 2025
  • 175 Pages
  • Global
From
Colorectal Cancer Drugs Market Report 2025 - Product Thumbnail Image

Colorectal Cancer Drugs Market Report 2025

  • Report
  • March 2025
  • 175 Pages
  • Global
From
Hepatocellular Carcinoma Drugs Market Report 2025 - Product Thumbnail Image

Hepatocellular Carcinoma Drugs Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
Metastatic Colorectal Cancer - Pipeline Insight, 2025 - Product Thumbnail Image

Metastatic Colorectal Cancer - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 280 Pages
  • Global
From
Neuroendocrine Tumors - Pipeline Insight, 2025 - Product Thumbnail Image

Neuroendocrine Tumors - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 280 Pages
  • Global
From
Biliary Tract Cancer (BTC)- Pipeline Insight, 2025 - Product Thumbnail Image

Biliary Tract Cancer (BTC)- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 180 Pages
  • Global
From
Metastatic Urothelial Carcinoma- Pipeline Insight, 2025 - Product Thumbnail Image

Metastatic Urothelial Carcinoma- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 150 Pages
  • Global
From
Esophageal Squamous Cell Carcinoma - Pipeline Insight, 2025 - Product Thumbnail Image

Esophageal Squamous Cell Carcinoma - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 150 Pages
  • Global
From
Synovial Sarcoma Pipeline Analysis Report - Product Thumbnail Image

Synovial Sarcoma Pipeline Analysis Report

  • Report
  • August 2024
  • 150 Pages
  • Global
From
Colorectal Cancer (CRC) Pipeline Analysis Report - Product Thumbnail Image

Colorectal Cancer (CRC) Pipeline Analysis Report

  • Report
  • August 2024
  • 150 Pages
  • Global
From
From
From
From
From
From
CTLA-4 inhibitors- Competitive landscape, 2023 - Product Thumbnail Image

CTLA-4 inhibitors- Competitive landscape, 2023

  • Report
  • May 2023
  • 220 Pages
  • Global
From
Loading Indicator

Ramucirumab is a monoclonal antibody used in the treatment of certain types of cancer. It is used in combination with other drugs to treat metastatic gastric cancer, metastatic non-small cell lung cancer, and metastatic colorectal cancer. It works by blocking the action of a protein called vascular endothelial growth factor (VEGF), which helps cancer cells grow and spread. Ramucirumab is approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Ramucirumab is a relatively new drug in the oncology market, but it has been gaining traction in recent years. It is used in combination with other drugs to treat a variety of cancers, and it has been shown to be effective in prolonging survival in some patients. It is also being studied in combination with other drugs for the treatment of other types of cancer. Some of the companies in the Ramucirumab market include Eli Lilly, AstraZeneca, Merck, and Pfizer. Show Less Read more